Xiangxue Pharmaceutical (300147) — Financial Flexibility Index
Xiangxue Pharmaceutical (300147) has a Financial Flexibility Index of 0.01x as of September 2025. Free cash flow of CN¥81.38 Million (operating CF CN¥75.64 Million minus capex CN¥5.74 Million) represents 0% of total liabilities (CN¥6.27 Billion). Also explore 300147 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Xiangxue Pharmaceutical Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Xiangxue Pharmaceutical across 19 annual periods. Check Xiangxue Pharmaceutical PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Xiangxue Pharmaceutical (2007–2025)
Year-by-year free cash flow to debt coverage for Xiangxue Pharmaceutical. For the full company profile including market capitalisation, see market cap of Xiangxue Pharmaceutical.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.02x | CN¥161.15 Million | CN¥139.63 Million | CN¥6.70 Billion | ▲ +172.8% |
| 2024 | 0.01x | CN¥53.42 Million | CN¥18.17 Million | CN¥6.06 Billion | ▼ -83.5% |
| 2023 | 0.05x | CN¥319.48 Million | CN¥263.44 Million | CN¥5.97 Billion | ▼ -41.2% |
| 2022 | 0.09x | CN¥594.65 Million | CN¥227.38 Million | CN¥6.53 Billion | ▼ -15.4% |
| 2021 | 0.11x | CN¥820.30 Million | CN¥257.56 Million | CN¥7.62 Billion | ▼ -38.4% |
| 2020 | 0.17x | CN¥964.60 Million | CN¥257.18 Million | CN¥5.53 Billion | ▲ +2.1% |
| 2019 | 0.17x | CN¥744.11 Million | CN¥83.02 Million | CN¥4.35 Billion | ▲ +34.5% |
| 2018 | 0.13x | CN¥586.70 Million | CN¥91.24 Million | CN¥4.61 Billion | ▼ -20.4% |
| 2017 | 0.16x | CN¥887.40 Million | CN¥109.53 Million | CN¥5.56 Billion | ▼ -68.2% |
| 2016 | 0.50x | CN¥2.16 Billion | CN¥198.48 Million | CN¥4.30 Billion | ▲ +27.3% |
| 2015 | 0.39x | CN¥436.84 Million | CN¥159.89 Million | CN¥1.11 Billion | ▲ +65.6% |
| 2014 | 0.24x | CN¥409.43 Million | CN¥165.58 Million | CN¥1.72 Billion | ▼ -35.0% |
| 2013 | 0.37x | CN¥646.92 Million | CN¥328.37 Million | CN¥1.76 Billion | ▼ -3.6% |
| 2012 | 0.38x | CN¥537.03 Million | CN¥118.91 Million | CN¥1.41 Billion | ▼ -26.6% |
| 2011 | 0.52x | CN¥260.24 Million | CN¥29.55 Million | CN¥502.16 Million | ▲ +141.1% |
| 2010 | 0.21x | CN¥102.33 Million | CN¥45.47 Million | CN¥476.01 Million | ▼ -21.7% |
| 2009 | 0.27x | CN¥99.04 Million | CN¥46.19 Million | CN¥360.69 Million | ▼ -49.6% |
| 2008 | 0.54x | CN¥193.44 Million | CN¥55.72 Million | CN¥354.94 Million | ▼ -30.2% |
| 2007 | 0.78x | CN¥282.75 Million | CN¥138.02 Million | CN¥361.98 Million | — |